Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.

Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.

Guselkumab for the treatment of moderate-to-severe plaque psoriasis in pediatric patients: results of the phase 3, randomized, placebo-controlled PROTOSTAR study.

Background: No currently approved treatment for pediatric plaque psoriasis selectively targets interleukin (IL)-23. In adults, guselkumab (a selective IL-23 inhibitor targeting the p19 subunit) demonstrated substantial efficacy with a favorable safety profile in treating moderate-to-severe plaque psoriasis.

Objective: PROTOSTAR (NCT03451851) evaluated the efficacy and safety of guselkumab in pediatric patients with moderate-to-severe plaque psoriasis.

Drought assessment through multiple indicators for Karnataka state, India.

Drought indices are imperative for determining the occurrence and impact of drought on crop production and society. Selecting appropriate indices to comprehensively assess the stress conditions is critical to analyze their effects on crops. The current study focuses on a comparative analysis of various indicators including the Standardized Precipitation Index (SPI), Standardized Water level Index (SWI), Standardized Reservoir Level Index (SRLI), Moderate Resolution Imaging Spectroradiometer (MODIS) Normalized Difference Vegetation Index (NDVI), NDVI Anomaly, Vegetation Condition Index (VCI), and Evaporative Stress Index (ESI).